anonymous
Guest
anonymous
Guest
If eCAP is so great, why wasn't it mentioned by the CEO on the 3rd quarter earnings report? Something so revolutionary should be worth mentioning to the investor community.
The "big" announcement was that eCAP has signed a deal with a GPO that supports a lot of hospitals. There was no announcement that a hospital has actually signed on for this program.
If a surgical patient is readmitted under this program, then S&N will pay for all of the non-reimbursed costs for this patient - now for the fine print, "up to the cost of the implants/equipment that hospital purchased for this one procedure." If S&N really has confidence in the product line's ability to stop readmissions, why not pay the cost to the hospital if Medicare penalizes them for readmissions or surgical site infections? That would be hundreds of thousands if not millions of dollars.
The value proposition to the hospital is this - you sign a contract with S&N and the S&N upside is that you are locked in to purchasing the entire product line. S&N downside is that if they fail, the hospital gets the product for that specific surgery for free. Hospital has no downside limit - they will have to pay for the entire patient stay and not be reimbursed for the entire readmission plus they are contractually obligated to keep buying S&N.
You spend millions with S&N, and in the event my product doesn't live up to the hype S&N reimburses you thousands. This doesn't seem like a fair proposition.
The "big" announcement was that eCAP has signed a deal with a GPO that supports a lot of hospitals. There was no announcement that a hospital has actually signed on for this program.
If a surgical patient is readmitted under this program, then S&N will pay for all of the non-reimbursed costs for this patient - now for the fine print, "up to the cost of the implants/equipment that hospital purchased for this one procedure." If S&N really has confidence in the product line's ability to stop readmissions, why not pay the cost to the hospital if Medicare penalizes them for readmissions or surgical site infections? That would be hundreds of thousands if not millions of dollars.
The value proposition to the hospital is this - you sign a contract with S&N and the S&N upside is that you are locked in to purchasing the entire product line. S&N downside is that if they fail, the hospital gets the product for that specific surgery for free. Hospital has no downside limit - they will have to pay for the entire patient stay and not be reimbursed for the entire readmission plus they are contractually obligated to keep buying S&N.
You spend millions with S&N, and in the event my product doesn't live up to the hype S&N reimburses you thousands. This doesn't seem like a fair proposition.